Skip to main content
. Author manuscript; available in PMC: 2022 Jan 1.
Published in final edited form as: Cancer Discov. 2021 Feb 15;11(7):1774–1791. doi: 10.1158/2159-8290.CD-20-1098

Figure 4.

Figure 4

(A) Schematic drawing showing pancreas epithelial cell-specific heterozygous deletion of Pthlh in the KPCY mouse pancreatic cancer model.

(B) Representative IHC images of PTHrP staining in pancreas from KPCY or KPCY-PthlhHET mice. Scale bars = 100μm.

(C-H) (C) Kaplan-Meier overall survival plots of KPCY or KPCY-PthlhHET mice cohorts. Logrank p=3.0×10−4. (D) Quantification of the percentage of mice with gross YFP+ metastases. (E) Quantification of endpoint pancreatic tumor mass normalized to body mass. (F) Quantification of endpoint liver mass normalized to body mass. (G) Quantification of endpoint lung mass normalized to body mass. (H) Representative brightfield and YFP images of pancreas, liver, and lungs at endpoint. Statistical analysis by Mann-Whitney U test (E) or Student’s unpaired t-test (F-G) with significance indicated (*, p<0.05; error bars indicate SD; n=41 mice and n=16 for KPCY or KPCY-PthlhHET cohorts, respectively).